Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis

International Journal of Artificial Organs

Volumn 23, Issue 1, 2000, Pages 27-32

  Yorioka, Noriaki ^a   Masaki, T ^a   Ito, T ^a   Kushihata, S ^a   Nishida, Y ^a   Taniguchi, Y ^a   Oda, H ^a   Yamakido, M ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

CAPD; Coagulation; Fibrinolysis; Lipid; Therapy

Indexed keywords

DIALYSIS; METABOLISM; PATIENT TREATMENT; PHYSIOLOGY; PROTEINS;

CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; FIBRINOLYSE; HAEMODIALYSIS; HYPERLIPIDEMIA; LIPID LEVELS; LIPID LOWERING; LIPID METABOLISMS; MEAN AGES; PERITONEAL DIALYSIS; THERAPY;

COAGULATION;

AGENTS AFFECTING LIPID METABOLISM; ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID ETHYL ESTER; LIPID; LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; PROTEIN; PROTEIN C; PROTEIN S; RECOMBINANT ERYTHROPOIETIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DIET THERAPY; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IMMUNOASSAY; LIPID METABOLISM; MALE; PERITONEAL DIALYSIS;

EID: 0034004406     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880002300105     Document Type: Article

References (34)

1. Merkus MP, Jager KJ, Dekker FW, et al. Quality of life in patients on chronic dialysis: Self-assessment 3 months after the start of treatment. Am J Kidney Dis 1997; 29: 584-92.
2. Saku K, Sasaki J, Naito S, Arakawa K. Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis. Nephron 1989; 51: 220-4.
3. Lal SM. Hyperlipidemia in continuous ambulatory peritoneal dialysis patients. ASAIO J 1993; 39: 87-8.
4. Anwar N, Bhatnagar D, Short CD, et al. Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialyis. Nephrol Dial Transplant 1993; 8: 71-4.
5. Bertoli M, Gasparotto ML, Vertolli U, Ruffatti A, Di Landro D, Romagnoli GF. Does hypercoagulability exist in CAPD patients? Int J Artif Organs 1984; 4: 237-9.
6. Vaziri ND, Shah GM Winer RL, et al. Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thromb Res 1989; 53: 173-80.
7. Gries E, Kopp J, Thomae U, Kuhlmann H. Relation of intraperitoneal and intravascular coagulation and fibrinolysis related antigens in peritoneal dialysis. Thromb Haemost 1990; 63: 356-60.
8. Jones CL, Andrew M, Eddy A, O'Neil M, Shalom NI, Balfe JW. Coagulation abnormalities in chronic peritoneal dialysis. Pediatr Nephrol 1990; 4: 152-5.
9. Yorioka N, Kobayashi M, Ogawa T, et al. Alterations of blood coagulation and fibrinolytic factors in patients undergoing CAPD. In: Ota K, Maher JF, Winchester JF, Hirszel P, eds. Current Concepts in Peritoneal Dialysis. Tokyo: Excerpta Medica; 1992. 709-12
10. Kim KJ, Yang WS, Kim SB, Lee SK, Park JS. Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin. Perit Dial Int 1997; 17: 157-161.
11. Irish AB. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis. Metabolism 1997; 46: 36-40.
12. Assouad M, Eknoyan G. Does the choice of renal replacement therapy adversely affect the hypercoagulability associated with renal disease? Am J Nephrol 1998; 18: 175-8.
13. Japanese Society for Dialysis Therapy. Causes of death by form of treatment in 1997. In: Maeda K, ed. An overview of regular dialysis treatment in Japan (as of Dec. 31, 1997). Tokyo: Japanese Society for Dialysis Therapy; 1998; 111.
14. Valderrábano F, Jones EHP, Mallick NP Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 1995; 10 (suppl 5): S1-25.
15. Held PJ, Port FK, Webb RL, et al. Causes of death. Am J Kidney Dis 1997; 30 (suppl I): S107-17.
16. Ma KW, Greene EL, Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; 19: 505-13.
17. Koch M, Kutkuhn B, Trenkwalder E, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein (a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997; 8: 1889-98.
18. Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1997; 76: 56-61
19. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169-83.
20. Wheeler DC. Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Int 1996; 50 (suppl 56): S41-6.
21. Kagan A. Bar-Khayim Y, Schafer Z, Fainaru M. Kinetics of peritoneal protein loss during CAPD: II Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 1990; 37: 980-90.
22. Attman PO, Samuelsson O, Alaupovic P, Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-92.
23. Balaskas EV, Bamihas GI, Tourkantonis A. Management of lipid abnormalities in patients on CAPD. Perit Dial Int 1997; 17: 308-9.
24. Wheeler DC. Should hyperlipidaemia in dialysis patients be treated? Nephrol Dial Transplant 1997; 12: 19-21.
25. Huffman CJ, Miller RH, Hultin MB. Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb 1992; 12: 267-70.
26. Bruckert E, De Sousa JC, Giral P et al. Interrelationship of plasma triglyceride and coagulant factor VII levels in normotriglyceridemic hypercholesterolemia. Atherosclerosis 1989; 75: 129-34.
27. Wada H, Moni Y, Kaneko T, et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993; 44: 112-6.
28. Zwaal RFA, Comfurius P, Bevers EM. Lipid-protein interactions in blood coagulation. Biochim Biophys Acta 1998; 1376: 433-53.
29. Tomura S, Nakamura Y, Doi M, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996; 27: 848-54
30. Mehrabian M, Peter JB, Barnard RJ, Lusis AJ. Dietary regulation of fibrinolytic factors. Atherosclerosis 1990; 84: 25-32.
31. Marckmann P, Toubro S, Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 1998; 52: 329-33.
32. Wada H, Mori Y, Kaneko T, et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992; 14: 829-34.
33. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani G. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Curr Ther Res 1994; 55: 1335-44.
34. Rosenson RS, Tangney CC. Antiatherothrombotic properities of statins. Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.